المؤلفون: Dimopoulos, Meletios A., Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G., Marlton, Paula, Wahlin, Björn E., Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J., Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey, Motta, Marina

المصدر: Journal of Clinical Oncology; 11/20/2023, Vol. 41 Issue 2, p5099-5106, 10p

المؤلفون: Kaiser, Martin F., Hall, Andrew, Walker, Katrina, Sherborne, Amy, De Tute, Ruth M., Newnham, Nicola, Roberts, Sadie, Ingleson, Emma, Bowles, Kristian, Garg, Mamta, Lokare, Anand, Messiou, Christina, Houlston, Richard S., Jackson, Graham, Cook, Gordon, Pratt, Guy, Owen, Roger G., Drayson, Mark T., Brown, Sarah R., Jenner, Matthew W.

المصدر: Journal of Clinical Oncology; 8/10/2023, Vol. 41 Issue 23, p3945-3955, 11p

المؤلفون: de Tute, Ruth M, Pawlyn, Charlotte, Cairns, David A, Davies, Faith E, Menzies, Tom, Rawstron, Andy, Jones, John R, Hockaday, Anna, Henderson, Rowena, Cook, Gordon, Drayson, Mark T, Jenner, Matthew W, Kaiser, Martin F, Gregory, Walter M, Morgan, Gareth J, Jackson, Graham H, Owen, Roger G

الوصف: PURPOSE Minimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when assessed at serial time points in the context of maintenance therapy after autologous stem-cell transplant (ASCT) and the interaction between MRD and molecular risk. METHODS Data from a large phase III trial (Myeloma XI) were examined to determine the relationship between MRD status, progression-free survival (PFS), and overall survival (OS) in post-ASCT patients randomly assigned to lenalidomide maintenance or no maintenance at 3 months after ASCT. MRD status was assessed by flow cytometry (median sensitivity 0.004%) before maintenance random assignment (ASCT + 3) and 6 months later (ASCT + 9). RESULTS At ASCT + 3, 475 of 750 (63.3%) patients were MRD-negative and 275 (36.7%) were MRD-positive. MRD-negative status was associated with improved PFS (hazard ratio [HR] = 0.47; 95% CI, 0.37 to 0.58 P < .001) and OS (HR = 0.59; 95% CI, 0.40 to 0.85; P = .0046). At ASCT + 9, 214 of 326 (65.6%) were MRD-negative and 112 (34.4%) were MRD-positive. MRD-negative status was associated with improved PFS (HR = 0.20; 95% CI, 0.13 to 0.31; P < .0001) and OS (HR = 0.33; 95% CI, 0.15 to 0.75; P = .0077). The findings were very similar when restricted to patients with complete response/near complete response. Sustained MRD negativity from ASCT + 3 to ASCT + 9 or the conversion to MRD negativity by ASCT + 9 was associated with the longest PFS/OS. Patients randomly assigned to lenalidomide maintenance were more likely to convert from being MRD-positive before maintenance random assignment to MRD-negative 6 months later (lenalidomide 30%, observation 17%). High-risk molecular features had an adverse effect on PFS and OS even for those patients achieving MRD-negative status. On multivariable analysis of MRD status, maintenance therapy and molecular risk maintained prognostic impact at both ASCT + 3 and ASCT + 9. CONCLUSION In patients with multiple myeloma, MRD status ...

وصف الملف: application/pdf

العلاقة: http://sro.sussex.ac.uk/id/eprint/105961/1/JCO%20MRD%20paper%20published%20version.pdfTest; de Tute, Ruth M, Pawlyn, Charlotte, Cairns, David A, Davies, Faith E, Menzies, Tom, Rawstron, Andy, Jones, John R, Hockaday, Anna, Henderson, Rowena, Cook, Gordon, Drayson, Mark T, Jenner, Matthew W, Kaiser, Martin F, Gregory, Walter M, Morgan, Gareth J, Jackson, Graham H and Owen, Roger G (2022) Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. Journal of Clinical Oncology. pp. 1-12. ISSN 0732-183X

الإتاحة: https://doi.org/10.1200/jco.21.02228Test
http://sro.sussex.ac.uk/id/eprint/105961Test/
http://sro.sussex.ac.uk/id/eprint/105961/1/JCO%20MRD%20paper%20published%20version.pdfTest

المؤلفون: de Tute, Ruth M., Pawlyn, Charlotte, Cairns, David A., Davies, Faith E., Menzies, Tom, Rawstron, Andy, Jones, John R., Hockaday, Anna, Henderson, Rowena, Cook, Gordon, Drayson, Mark T., Jenner, Matthew W., Kaiser, Martin F., Gregory, Walter M., Morgan, Gareth J., Jackson, Graham H., Owen, Roger G.

المصدر: Journal of Clinical Oncology; 9/1/2022, Vol. 40 Issue 25, p2889-2900, 12p

المؤلفون: Owen, Roger G

المصدر: Journal of Clinical Oncology; 2/20/2021, Vol. 39 Issue 6, p548-550, 3p

المؤلفون: Rawstron, Andy C., Child, J. Anthony, de Tute, Ruth M., Davies, Faith E., Gregory, Walter M., Bell, Sue E., Szubert, Alexander J., Navarro-Coy, Nuria, Drayson, Mark T., Feyler, Sylvia, Ross, Fiona M., Cook, Gordon, Jackson, Graham H., Morgan, Gareth J., Owen, Roger G.

المصدر: Journal of Clinical Oncology; 7/10/2013, Vol. 31 Issue 20, p2540-2547, 9p

المؤلفون: Rawstron, Andy C, Child, J Anthony, de Tute, Ruth M, Davies, Faith E, Gregory, Walter M, Bell, Sue E, Szubert, Alexander J, Navarro Coy, Nuria, Drayson, Mark T, Feyler, Sylvia, Ross, Fiona M, Cook, Gordon, Jackson, Graham H, Morgan, Gareth J, Owen, Roger G

المصدر: Journal of Clinical Oncology; 2/10/2014, Vol. 32 Issue 5, p476-477, 2p

المؤلفون: Rawstron, Andy C., Child, J. Anthony, de Tute, Ruth M., Davies, Faith E., Gregory, Walter M., Bell, Sue E., Szubert, Alexander J., Navarro Coy, Nuria, Drayson, Mark T., Feyler, Sylvia, Ross, Fiona M., Cook, Gordon, Jackson, Graham H., Morgan, Gareth J., Owen, Roger G.

المصدر: Journal of Clinical Oncology; 2/10/2014, Vol. 32 Issue 5, p476-477, 2p